415 related articles for article (PubMed ID: 33750078)
1. Off-the-Shelf Chimeric Antigen Receptor T Cells: How Do We Get There?
Watanabe N; Mamonkin M
Cancer J; 2021 Mar-Apr 01; 27(2):176-181. PubMed ID: 33750078
[TBL] [Abstract][Full Text] [Related]
2. Use of Cell and Genome Modification Technologies to Generate Improved "Off-the-Shelf" CAR T and CAR NK Cells.
Morgan MA; Büning H; Sauer M; Schambach A
Front Immunol; 2020; 11():1965. PubMed ID: 32903482
[TBL] [Abstract][Full Text] [Related]
3. The paths and challenges of "off-the-shelf" CAR-T cell therapy: An overview of clinical trials.
Moradi V; Omidkhoda A; Ahmadbeigi N
Biomed Pharmacother; 2023 Dec; 169():115888. PubMed ID: 37979380
[TBL] [Abstract][Full Text] [Related]
4. Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma.
Sommer C; Boldajipour B; Kuo TC; Bentley T; Sutton J; Chen A; Geng T; Dong H; Galetto R; Valton J; Pertel T; Juillerat A; Gariboldi A; Pascua E; Brown C; Chin SM; Sai T; Ni Y; Duchateau P; Smith J; Rajpal A; Van Blarcom T; Chaparro-Riggers J; Sasu BJ
Mol Ther; 2019 Jun; 27(6):1126-1138. PubMed ID: 31005597
[TBL] [Abstract][Full Text] [Related]
5. Translational Implications for Off-the-shelf Immune Cells Expressing Chimeric Antigen Receptors.
Torikai H; Cooper LJ
Mol Ther; 2016 Aug; 24(7):1178-86. PubMed ID: 27203439
[TBL] [Abstract][Full Text] [Related]
6. Strategies for overcoming bottlenecks in allogeneic CAR-T cell therapy.
Lv Z; Luo F; Chu Y
Front Immunol; 2023; 14():1199145. PubMed ID: 37554322
[TBL] [Abstract][Full Text] [Related]
7. Allogeneic Chimeric Antigen Receptor Therapy in Lymphoma.
Khurana A; Lin Y
Curr Treat Options Oncol; 2022 Feb; 23(2):171-187. PubMed ID: 35212892
[TBL] [Abstract][Full Text] [Related]
8. "Off-the-Shelf" Allogeneic CAR Cell Therapy-Neglected HvG Effect.
An Y; Jin X; Zhang H; Zhang M; Mahara S; Lu W; Zhao M
Curr Treat Options Oncol; 2023 May; 24(5):409-441. PubMed ID: 37010679
[TBL] [Abstract][Full Text] [Related]
9. Allogeneic chimeric antigen receptor-modified cells for adoptive cell therapy of cancer.
Marcus A; Eshhar Z
Expert Opin Biol Ther; 2014 Jul; 14(7):947-54. PubMed ID: 24661086
[TBL] [Abstract][Full Text] [Related]
10. Allogeneic double-negative CAR-T cells inhibit tumor growth without off-tumor toxicities.
Vasic D; Lee JB; Leung Y; Khatri I; Na Y; Abate-Daga D; Zhang L
Sci Immunol; 2022 Apr; 7(70):eabl3642. PubMed ID: 35452255
[TBL] [Abstract][Full Text] [Related]
11. Off-the-Shelf Allogeneic T Cell Therapies for Cancer: Opportunities and Challenges Using Naturally Occurring "Universal" Donor T Cells.
Perez C; Gruber I; Arber C
Front Immunol; 2020; 11():583716. PubMed ID: 33262761
[TBL] [Abstract][Full Text] [Related]
12. Off the shelf T cell therapies for hematologic malignancies.
McCreedy BJ; Senyukov VV; Nguyen KT
Best Pract Res Clin Haematol; 2018 Jun; 31(2):166-175. PubMed ID: 29909917
[TBL] [Abstract][Full Text] [Related]
13. Strategies to Circumvent the Side-Effects of Immunotherapy Using Allogeneic CAR-T Cells and Boost Its Efficacy: Results of Recent Clinical Trials.
Smirnov S; Petukhov A; Levchuk K; Kulemzin S; Staliarova A; Lepik K; Shuvalov O; Zaritskey A; Daks A; Fedorova O
Front Immunol; 2021; 12():780145. PubMed ID: 34975869
[TBL] [Abstract][Full Text] [Related]
14. Strategies to overcome the side effects of chimeric antigen receptor T cell therapy.
Mirzaee Godarzee M; Mahmud Hussen B; Razmara E; Hakak-Zargar B; Mohajerani F; Dabiri H; Fatih Rasul M; Ghazimoradi MH; Babashah S; Sadeghizadeh M
Ann N Y Acad Sci; 2022 Apr; 1510(1):18-35. PubMed ID: 34982476
[TBL] [Abstract][Full Text] [Related]
15. Innate and Innate-Like Cells: The Future of Chimeric Antigen Receptor (CAR) Cell Therapy.
Cortés-Selva D; Dasgupta B; Singh S; Grewal IS
Trends Pharmacol Sci; 2021 Jan; 42(1):45-59. PubMed ID: 33250273
[TBL] [Abstract][Full Text] [Related]
16. Paving the Way Towards Universal Chimeric Antigen Receptor Therapy in Cancer Treatment: Current Landscape and Progress.
Zhang Y; Li P; Fang H; Wang G; Zeng X
Front Immunol; 2020; 11():604915. PubMed ID: 33362790
[TBL] [Abstract][Full Text] [Related]
17. [Advances in Allogeneic Chimeric Antigen Receptor T Cells].
Zhao Q; Li F
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2023 Dec; 45(6):967-972. PubMed ID: 38173109
[TBL] [Abstract][Full Text] [Related]
18. Engineering Tolerance toward Allogeneic CAR-T Cells by Regulation of MHC Surface Expression with Human Herpes Virus-8 Proteins.
Wang X; Cabrera FG; Sharp KL; Spencer DM; Foster AE; Bayle JH
Mol Ther; 2021 Feb; 29(2):718-733. PubMed ID: 33554868
[TBL] [Abstract][Full Text] [Related]
19. Chimeric Antigen Receptor T-Cell Therapy: Current Perspective on T Cell-Intrinsic, T Cell-Extrinsic, and Therapeutic Limitations.
Brookens SK; Posey AD
Cancer J; 2023 Jan-Feb 01; 29(1):28-33. PubMed ID: 36693155
[TBL] [Abstract][Full Text] [Related]
20. Release Assays and Potency Assays for CAR T-Cell Interventions.
Dias J; Cadiñanos-Garai A; Roddie C
Adv Exp Med Biol; 2023; 1420():117-137. PubMed ID: 37258787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]